SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on July 3, 2003; DOI 10.1182/blood-2003-04-1180. This Article Full Text (PDF) All Versions of this Article: 2003-04-1180v1 102/8/3068    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lee, S. Articles by Kim, C.-C. Search for Related Content PubMed PubMed Citation Articles by Lee, S. Articles by Kim, C.-C. Social Bookmarking                   What's this? Submitted April 16, 2003 Accepted June 12, 2003 Minimal residual disease-based role of imatinib mesylate as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia Seok Lee*, Dong-Wook Kim, Yoo-Jin Kim, Nak-Gyun Chung, Yoo-Li Kim, Ji-Yeon Hwang, and Chun-Choo Kim Catholic HSCT Center, The Catholic University of Korea, Seoul, Korea * Corresponding author; email: leeseok{at}catholic.ac.kr. Fourteen adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were analyzed to evaluate the role of imatinib prior to allogeneic stem cell transplantation (SCT). Of these, 12 patients were in complete hematological response (CHR), and 2 were refractory. Imatinib was administered as an interim schedule after each chemotherapy course. After the 1st imatinib cycle, 11 patients remained in sustained CHR with a decrease in the BCR-ABL/ABL ratios (0.89 logs), and 1 refractory patient achieved CHR. Meanwhile, 2 patients were resistant to imatinib. Ten patients receiving a 2nd imatinib cycle following consolidation showed sustained CHR, including 2 molecular CR, with a further decrease in the BCR-ABL/ABL ratios (0.19 logs). Twelve patients underwent SCT in a favorable status, and of these, 11 are still alive in a leukemia-free status (9-28+ months post-SCT). First-line imatinib interim therapy appears to be a useful strategy to bridge the time to SCT for Ph+ ALL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Raff, N. Gokbuget, S. Luschen, R. Reutzel, M. Ritgen, S. Irmer, S. Bottcher, H.-A. Horst, M. Kneba, D. Hoelzer, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials Blood, February 1, 2007; 109(3): 910 - 915. [Abstract] [Full Text] [PDF] S. Lee, Y.-J. Kim, C.-K. Min, H.-J. Kim, K.-S. Eom, D.-W. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Blood, May 1, 2005; 105(9): 3449 - 3457. [Abstract] [Full Text] [PDF] L. Seok, Y.-J. Kim, C.-K. Min, H.-J. Kim, K.-S. Eom, D.-W. Kim, J.-W. Lee, W.-S. Min, and C.-C. Kim Imatinib Interim Therapy Has Favorable Impact on the Outcome of Patients with Ph+ ALL Treated with Allogeneic SCT. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2740 - 2740. [Abstract]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020